Related Experiment Video
Updated: Jun 14, 2026
Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells
Takahiro Tsuji1,2, Haruka Hirose3, Daisuke Sugiyama4
1Department of Anatomy and Molecular Cell Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Abstract:
Brain metastases are frequent and often lethal complications of advanced cancers. Microglia, resident immune cells of the brain, are known to exert both anti- and protumor functions in late-stage metastases; however, their response during the initial outgrowth of metastatic lesions is not well characterized. Understanding how heterogeneous microglial subgroups are regulated in the developing tumor microenvironment could pave the way for therapeutic strategies to eliminate metastatic tumors at an early stage. In this study, we used a combination of in vivo fate map imaging, single-cell RNA sequencing, and a holographic photoconversion-based technique (opto-omics) to track tumor fate and early microglial responses over time in the same animals during the colonization of disseminated tumor cells. The microglial population was transcriptionally and morphologically heterogeneous, comprising both pro- and antitumor subsets. Genetic and pharmacologic perturbations revealed that microglial phenotypes could be shifted by inhibiting TGFβ signaling or by deleting the tumor cell surface antigens CD24 and CD47. These findings reveal targetable plasticity in early-stage microglial responses to brain metastasis and suggest that harnessing prophagocytic microglial states may offer a therapeutic window before systemic immunosuppression becomes dominant.
Significance:
In vivo imaging with optical labeling and transcriptomics reveals heterogeneous microglia and identifies that CD24/CD47 loss or TGFβ modulation alters subpopulation fate, exposing a therapeutic window and actionable targets for brain metastases. See related commentary by Vallebuona and Smalley, p. 1345.
Insights
Researchers uncovered how brain immune cells called microglia respond to early-stage brain metastases. Modulating these microglia may offer new therapeutic strategies for eliminating tumors before they spread.
Area of Science:
- Neuroscience
- Immunology
- Oncology
Background:
- Brain metastases are a common and fatal outcome of advanced cancers.
- Microglia, the brain's immune cells, have complex roles in established tumors, but their early-stage functions are unclear.
- Understanding early microglial responses is crucial for developing therapies against nascent brain tumors.
Purpose of the Study:
- To investigate the dynamic behavior and heterogeneity of microglial populations during the initial development of brain metastases.
- To identify molecular mechanisms regulating microglial phenotypes in the early tumor microenvironment.
- To explore therapeutic strategies targeting microglia for early intervention against brain metastasis.
Main Methods:
- In vivo fate mapping and time-lapse imaging to track tumor cells and microglia.
- Single-cell RNA sequencing to analyze microglial transcriptional heterogeneity.
- Opto-omics (holographic photoconversion) for precise spatiotemporal manipulation.
- Genetic and pharmacological interventions to perturb microglial responses.
Main Results:
- Microglia exhibited significant transcriptional and morphological heterogeneity, with distinct pro- and anti-tumor subsets identified.
- Inhibiting transforming growth factor-beta (TGF-β) signaling altered microglial phenotypes.
- Deleting tumor cell surface antigens CD24a and CD47 modulated microglial states.
- Early microglial responses show plasticity that can be therapeutically targeted.
Conclusions:
- Microglial heterogeneity plays a critical role in the early stages of brain metastasis.
- Targeting TGF-β signaling or specific tumor antigens can reprogram microglia towards an anti-tumor state.
- Harnessing pro-phagocytic microglial functions presents a potential therapeutic window for early brain metastasis intervention.
Related Concept Videos
02:21Cancers Originate from Somatic Mutations in a Single Cell
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...